Shots:

• The BTD is based on P-II 1346.9 clinical trial- which demonstrated that BI 425809 improved cognition in adult patients with schizophrenia
• Moreover- the company has initiated the P-III CONNEX program assessing the safety and efficacy of BI 425809 vs PBO for improving cognition in adults with schizophrenia over a 26wks. treatment period
• Additionally- Boehringer Ingelheim will also use VeraSci's VRFCAT which is an assessment that improves clinical trials by detecting functional improvements in patients' everyday lives. BI 425809 is a novel glycine transporter-1 (GlyT1) inhibitor

  Ref: PRNewswire | Image: Pharmaceutical Technology